Literature DB >> 17372475

Nonketotic hyperglycinemia: A life-threatening disorder in Saudi newborns.

N Haider1, M A Salih, S Al-Rasheed, S Al-Mofada, P M Krahn, M Kabiraj.   

Abstract

Nonketotic hyperglycinemia (NKH) is an autosomal recessive disorder due to a fundamental defect in the glycine cleavage system, which leads to neuronal dysfunction caused by two receptor-mediated mechanisms. It is a life-threatening condition in the neonate. Until now, the disease has not been described from Saudi Arabia. We report on three Saudi newborns (two males and one female) who had NKH. Two of these were siblings (male and female). Following uneventful deliveries, they presented between the first and third day of life with progressive lethargy, poor feeding, recurrent apnea and severe hypotonia. Two newborns had myoclonic seizures, whereas electroencephalogram showed burst-suppression pattern in all of them. The diagnosis was confirmed by high cerebrospinal fluid/plasma glycine ratio (0.2 and 1.08) in two patients (normal < 0.030, whereas a sibling of one of the neonates had a high glycine level. Both siblings died during the second month of life despite therapy with dextromethorphan (an N-methyl-D-asparate [NMDA] receptor antagonist) in one of them. The third day had ketamine (noncompetitive NMDA receptor antagonist) and sodium benzoate (that conjugates with glycine, forming nontoxic hippuric acid). Although his seizures were controlled, he survived with severe neurological sequelae.

Entities:  

Year:  1996        PMID: 17372475     DOI: 10.5144/0256-4947.1996.400

Source DB:  PubMed          Journal:  Ann Saudi Med        ISSN: 0256-4947            Impact factor:   1.526


  2 in total

Review 1.  Recognition and diagnostic approach to acute metabolic disorders in the neonatal period.

Authors:  Sarar Mohamed
Journal:  Sudan J Paediatr       Date:  2011

2.  Nonketotic hyperglycinemia in Suleimaniah Children's Hospital, Riyadh, Saudi Arabia.

Authors:  Devabrata Roy; Ali Al-Asmari; Yousef K Ghazal; Saleh Al-Oqiel
Journal:  Ann Saudi Med       Date:  2004 Sep-Oct       Impact factor: 1.526

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.